Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359729 | 0.74 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL7060297 | 0.74 | CHRNA7 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL6360574 | 0.73 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7161292 | 0.69 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28544293 | 0.65 | MAPT (0.44) | — | |
| SCHEMBL6357471 | 0.63 | CHRNB4 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7661467 | 0.61 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6358950 | 0.60 | CHRNB4 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6663087 | 0.60 | CHRNB4 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6357474 | 0.59 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | CHRNB2 19/4885CHRNA4 4/4885CHRNB4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.